MedTrace Logo

A Pilot Study of Alefacept for the Treatment of Pityriasis Rubra Pilaris

NCT00815633 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2018-05-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether the biologic medication alefacept (Amevive) is effective and safe in the treatment of Pityriasis Rubra Pilaris.

Conditions

  • Pityriasis Rubra Pilaris

Interventions

DRUG

Alefacept

15mg intramuscular injection weekly for 12 weeks

Sponsors & Collaborators

  • Astellas Pharma Inc

    collaborator INDUSTRY

  • Joshua Zeichner

    lead OTHER

Principal Investigators

  • Joshua Zeichner, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-06-30
Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00815633 on ClinicalTrials.gov